Lilly's partnership signals growing industry recognition of AI-driven speech analysis as a path to predicting Alzheimer's disease risk NEW YORK, Oct. 28, 2026 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA) announces a new collaboration...
Hence then, the article about alzheimer s drug discovery foundation s diagnostics accelerator licenses speechdx dataset to eli lilly and company advancing speech based markers as a critical alzheimer s research tool was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator Licenses SpeechDx Dataset to Eli Lilly and Company, Advancing Speech-Based Markers as a Critical Alzheimer's Research Tool )
Also on site :
- Frank Lloyd Wright’s Price Tower sold for $10 in 2023; in 2025, a court-approved sale brought in $1.4 million
- Who Won ‘The Challenge: Cutthroat’? Season 42 Winners Revealed
- Clarks’ Tassel Slip-On Loafers Are ‘Great for Work and Everyday,’ Now Up to 58% Off